HFT Trading Indictment, page-17

Allied Healthcare Demonstrates Positive Results in Tissue Heart Valve Study
• Study demonstrates reduction in visible calcification of implanted tissue heart valves
• ADAPT process has the potential to offer patients and surgeons ‘longer life’ tissue valves
• Commercial distribution discussions progressing for CardioCel
PERTH, Australia, ## October 2011
Allied Healthcare Group Limited (ASX: AHZ) today announced positive results from a preclinical trial
of its ADAPT® Tissue Engineering technology in heart valves. The Tissue Heart Valve Study was
jointly conducted by Allied Healthcare Group’s subsidiary Celxcel Pty Ltd and a global tissue heart
valve manufacturer.
The study compared the performance (biocompatibility and calcification potential) of the heart
valve tissue, treated with the ADAPT anti‐cytotoxic and anti‐calcification process, plus Celxcel’s
terminal sterilization method.
The study demonstrated all forms of the commercial heart valve tissue developed calcification over
the 24 weeks. The tissue subjected to Celxcel’s terminal sterilization method showed significantly
reduced levels of calcification, whilst the tissue subjected to the ADAPT anti‐calcification
engineering process, plus the terminal sterilization method demonstrated the lowest levels of
calcification during the entire study.
Calcification of tissue heart valves shortens the lifespan of implanted tissue. This often results in
clinicians choosing to use mechanical valves, which requires patients to undergo lifelong and
complicated anticoagulant therapy.
“The results were in line with our expectations and very positive,” said Allied Healthcare Managing
Director Lee Rodne. The results open up the possibility of extending the lifespan of implanted tissue
valves dramatically. At the moment the build up of calcification means that implanted heart valve
tissue has a shorter lifespan of around 10 years when compared to mechanical valves which is over
20 years.”
Bob Atwill Celxcel CEO said, “With the ADAPT process we are aiming to increase the lifespan of
tissue heart valves to allow them to become the “product of choice” for surgeons around the world.
This will allow more patients to be free of the need to be tied to complicated anticoagulant therapy
for the rest of their lives”.